Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Gomes,M.B. (2) Albanesi,F.M. (1) Chazan,A.C.S. (1) Cohen,C. (1) Gonçalves,M.F.R. (1) Neves,R. (1) Mais... Palavra-chave C-peptide (2) Diabetes mellitus type 2 (1) Diabetes type 1 (1) Microalbuminuria (1) Retinopathy (1) Secondary failure (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2001 (1) 2000 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Residual ß-cell function and microvascular complications in type 1 diabetic patients BJMBR Gomes,M.B.; Gonçalves,M.F.R.; Neves,R.; Cohen,C.; Albanesi,F.M.. To determine the influence of residual ß-cell function on retinopathy and microalbuminuria we measured basal C-peptide in 50 type 1 diabetic outpatients aged 24.96 ± 7.14 years, with a duration of diabetes of 9.1 ± 6.2 years. Forty-three patients (86%) with low C-peptide (&lt;0.74 ng/ml) had longer duration of diabetes than 7 patients (14%) with high C-peptide (<FONT FACE="Symbol">³</font>0.74 ng/ml) (9 (2-34) vs 3 (1-10) years, P = 0.01) and a tendency to high glycated hemoglobin (HBA1) (8.8 (6-17.9) vs 7.7 (6.9-8.7)%, P = 0.08). Nine patients (18%) had microalbuminuria (two out of three overnight urine samples with an albumin excretion rate (AER) <FONT FACE="Symbol">³</font>20 and &lt;200 µg/min) and 13 (26%) had... Tipo: Info:eu-repo/semantics/article Palavras-chave: C-peptide; Microalbuminuria; Retinopathy; Diabetes type 1. Ano: 2000 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000200008 Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure BJMBR Chazan,A.C.S.; Gomes,M.B.. To determine the effects of combined therapy of gliclazide and bedtime insulin on glycemic control and C-peptide secretion, we studied 25 patients with type 2 diabetes and sulfonylurea secondary failure, aged 56.8 ± 8.3 years, with a duration of diabetes of 10.6 ± 6.6 years, fasting plasma glucose of 277.3 ± 64.6 mg/dl and a body mass index of 27.4 ± 4.8 kg/m². Patients were submitted to three therapeutic regimens lasting 2 months each: 320 mg gliclazide (phase 1), 320 mg gliclazide and bedtime NPH insulin (phase 2), and insulin (phase 3). At the end of each period, glycemic and C-peptide curves in response to a mixed meal were determined. During combined therapy, there was a decrease in all glycemic curve values (P<0.01). Twelve patients (48%) reached... Tipo: Info:eu-repo/semantics/article Palavras-chave: Diabetes mellitus type 2; C-peptide; Secondary failure. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000100006 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco